<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Objectives: <z:hpo ids='HP_0000020'>Urinary incontinence</z:hpo> arising in <z:hpo ids='HP_0000726'>dementia</z:hpo> lowers patient quality of life, predicts caregiver burden and nursing home placement, and predisposes to adding additional medicines that can further impair cognition, behavior, and function </plain></SENT>
<SENT sid="1" pm="."><plain>An understanding of <z:e sem="disease" ids="C0021167" disease_type="Disease or Syndrome" abbrv="">incontinence</z:e> pharmacology can help the clinician predict and manage this adverse event in treating patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Experimental Design: Case report </plain></SENT>
<SENT sid="3" pm="."><plain>Principal Observations:We encountered a patient with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> who developed <z:hpo ids='HP_0000020'>urinary incontinence</z:hpo> and <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> when <z:chebi fb="0" ids="10119">ziprasidone</z:chebi> was added to the regimen for behavioral concerns.When he was switched to <z:chebi fb="0" ids="36796">duloxetine</z:chebi>, the <z:e sem="disease" ids="C0021167" disease_type="Disease or Syndrome" abbrv="">incontinence</z:e> and <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> resolved whereas improvements in <z:e sem="disease" ids="C0233651" disease_type="Mental or Behavioral Dysfunction" abbrv="">perseveration</z:e>, <z:hpo ids='HP_0000737'>irritability</z:hpo>, <z:hpo ids='HP_0011999'>paranoia</z:hpo>, and <z:hpo ids='HP_0000713'>agitation</z:hpo> persisted </plain></SENT>
<SENT sid="4" pm="."><plain>Conclusions:While a pharmacokinetic explanation is unlikely, the best evidence suggests that <z:chebi fb="0" ids="10119">ziprasidone</z:chebi>-mediated <z:chebi fb="19" ids="28790">serotonin</z:chebi> 5HT2 receptor blockade may explain the reversible <z:e sem="disease" ids="C0021167" disease_type="Disease or Syndrome" abbrv="">incontinence</z:e>, with an adrenergic alpha-1 receptor mechanism considered to be less likely </plain></SENT>
<SENT sid="5" pm="."><plain>Patients on 5HT2 <z:chebi fb="68" ids="48706">antagonist</z:chebi> drugs, including atypical <z:chebi fb="0" ids="35476">antipsychotics</z:chebi>, should be observed for <z:e sem="disease" ids="C0021167" disease_type="Disease or Syndrome" abbrv="">incontinence</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In the event of <z:e sem="disease" ids="C0021167" disease_type="Disease or Syndrome" abbrv="">incontinence</z:e> developing in the context of these agents, <z:chebi fb="0" ids="36796">duloxetine</z:chebi> may represent a potential pharmacological alternative in some cases </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="36796">Duloxetine</z:chebi> may improve neuropsychiatric symptoms in <z:hpo ids='HP_0000726'>dementia</z:hpo> through its effects on <z:chebi fb="19" ids="28790">serotonin</z:chebi>, <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi>, and frontal <z:chebi fb="40" ids="18243">dopamine</z:chebi> </plain></SENT>
</text></document>